In vitro activity of para-guanidinoethylcalix[4]arene against susceptible and antibiotic-resistant Gram-negative and Gram-positive bacteria

Journal of Antimicrobial Chemotherapy

Volumn 60, Issue 3, 2007, Pages 575-581

  Grare, Marion ^a   Mourer, Maxime ^a   Fontanay, Stéphane ^a   Regnouf de Vains, Jean Bernard ^a   Finance, Chantal ^a   Duval, Raphaël Emmanuel ^a  

^a UNIVERSITÉ DE LORRAINE   (France)

Author keywords

Antibacterial agent; Calixarene; CC50; IC50; Selectivity index

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; 4 GUANIDINOETHYLCALIX[4]ARENE; 4 GUANIDINOETHYLPHENOL; AMOXICILLIN; ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; ANTITRYPANOSOMAL AGENT; CALIXARENE; DECAMETHYLENEDIGUANIDINE DIHYDROCHLORIDE; HEXAMIDINE; NEUTRAL RED; OXACILLIN; TICARCILLIN; UNCLASSIFIED DRUG; VANCOMYCIN;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIOSTASIS; CONTROLLED STUDY; CYTOTOXICITY; DOSE TIME EFFECT RELATION; DRUG MECHANISM; DRUG SCREENING; DRUG STRUCTURE; ENTEROCOCCUS FAECALIS; ESCHERICHIA COLI; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HUMAN; HUMAN CELL; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANCE; NONHUMAN; PSEUDOMONAS AERUGINOSA; STAPHYLOCOCCUS AUREUS; STRUCTURE ACTIVITY RELATION;

ANTI-BACTERIAL AGENTS; BENZAMIDINES; CALIXARENES; CELL LINE, TUMOR; CELL SURVIVAL; DRUG RESISTANCE, BACTERIAL; GRAM-NEGATIVE BACTERIA; GRAM-POSITIVE BACTERIA; GUANIDINES; HUMANS; MICROBIAL SENSITIVITY TESTS; NEUTRAL RED; STRUCTURE-ACTIVITY RELATIONSHIP; TETRAZOLIUM SALTS; THIAZOLES;

EID: 34548118781     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkm244     Document Type: Article

References (36)

1. European Antimicrobial Resistance Surveillance System (EARSS). Annual Report 2005. Data summary from January 1999 through December 2005, issued October 2006. http://www.rivm.nl/earss/Images/ EARSS%202005_tcm61-34899.pdf.
2. Lepoutre A, Branger B, Garleau N et al. Enquête nationale de prévalence des infections hosocomiales en France (2001) reported through the Réseau National de Surveillance et d'Investigation des Infections Nosocomiales (RAISIN), Institut de Veille Sanitaire (InVS): 2004. http://212.234.146.165/publications/2003/raisin_enp_2001/ raisin_enp_2001_p_19_50.pdf.
3. National Nosocomial Infections Surveillance (NNIS). System Report. Data summary from January 1992 through June 2004. Am J Infect Control 2004; 32: 470-85.
4. Smith T, Pearson ML, Wilcox KR et al. Glycopeptide-Intermediate Staphylococcus aureus Working Group. Emergence of vancomycin resistance in Staphylococcus aureus. N Engl J Med 1999; 340: 493-501.
5. Appelbaum PC. The emergence of vancomycin-intermediate and vancomycin-resistant Staphylococcus aureus. Clin Microbiol Infect 2006; 12: 16-23.
6. Bonora MG, Solbiati M, Stepan E et al. Emergence of linezolid resistance in the vancomycin-resistant Enterococcus faecium multi-locus sequence typing C1 epidemic lineage. J Clin Microbiol 2006; 44: 1153-5.
7. Martinez-Martinez L, Pascual A, Jacoby GA. Quinolone resistance from a transferable plasmid. Lancet 1998; 351: 797-9.
8. Coveney D, Costello B. Calixarene-derivatives having anti-viral activity. European Patent, December 2003 EP 1367044A1.
9. Coveney D, Costello B. Antiviral-compounds. US Patent, May 2005 05/ 0113454A1.
10. Harris SJ. Calixarene-based compounds having antibacterial, antifungal, anticancer-HIV activity. WO Patent, July 1995 95/19974.
11. Harris SJ. Anti-viral compounds. WO Patent, June 2002 02/44121.
12. Hwang KM, Qi YM, Liu SY et al. Inhibition and treatment of infection by enveloped virus with calix(n)arene compounds. WO Patent, February 1994 94/03164.
13. Comforth JW, Hart PD, Nicholls GA et al. Antituberculous effects of certain surface-active polyoxyethylene ethers. Br J Pharmacol Chemother 1955; 10: 73-88.
14. Colston MJ, Hailes HC, Stavropoulos E et al. Antimycobacterial calixarenes enhance innate defense mechanisms in murine macrophages and induce control of Mycobacterium tuberculosis infection in mice. Infect Immun 2004; 72: 6318-23.
15. Hart PD, Armstrong JA, Brodaty E. Calixarenes with host-mediated potency in experimental tuberculosis: Further evidence that macrophage lipids are involved in their mechanism of action. Infect Immun 1996; 64: 1491-3.
16. Casnati A, Di Modugno E, Fabbi M et al. Synthesis, antimicrobial activity and binding properties of calix[4]arene based vancomycin mimics. Bioorg Med Chem Lett 1996; 6: 2699-704.
17. Williams DH, Bardsley B. The vancomycin group of antibiotics and the fight against resistant bacteria. Angew Chem Int Ed Engl 1999; 38: 1172-93.
18. Ostenson CG. Effect of the biguanide synthalin A on the pancreatic A2-cell of the guinea pig. Exp Clin Endocrinol 1983; 81: 255-62.
19. Ollivier G, Legros D. Human African trypanosomiasis: A history of its therapies and their failures. Trop Med Int Health 2001; 6: 855-63.
20. Mourer M, Duval RE, Finance C et al. Functional organisation and gain of activity: The case of the antibacterial para guanidinoethylcalix[4]arene. Bioorg Med Chem Lett 2006; 16 2960-3.
21. National Committee for Clinical Laboratory Standards. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically: Approved Standard M7-A6. NCCLS, Wayne, PA, USA, 2003.
22. CA-SFM. Communiqué 2007 (Edition janvier 2007). http://www.sfm.asso.fr/nouv/general.php?pa=2.
23. Livermore DM. Tigecycline: What is it, and where should it be used? J Antimicrob Chemother 2005; 56: 611-4.
24. Fauchere JL, Avril JL. Antibiotiques. In: Bactériologie Générale et Médicale. Paris, France: Ellipses, 2002; 149-76.
25. Fusenig NE, Boukamp P. Multiple stages and genetic alterations in immortalization, malignant transformation, and tumor progression of human skin keratinocytes. Mol Carcinog 1998; 23: 144-58.
26. Damour O, Zhi Hua S, Lasne F et al. Cytotoxicity evaluation of antiseptics and antibiotics on cultured human fibroblasts and keratinocytes. Burns 1992; 18: 479-85.
27. Wilson JR, Mills JG, Prather ID et al. A toxicity index of skin and wound cleansers used on in vitro fibroblasts and keratinocytes. Adv Skin Wound Care 2005; 18: 373-8.
28. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 198; 65: 55-63.
29. Harmand PO, Duval R, Delage C et al. Ursolic acid induces apoptosis through mitochondrial intrinsic pathway and caspase-3 activation in M4Beu melanoma cells. Int J Cancer 2005; 114: 1-11.
30. Borenfreund E, Puemer JA. Toxicity determined in vitro by morphological alterations and neutral red absorption. Toxicol Lett 1985; 24: 119-24.
31. Fluit AC, Schmitz FJ, Verhoef J et al. In vitro activity of daptomycin against Gram-positive European clinical isolates with defined resistance determinants. Antimicrob Agents Chemother 2004; 48 1007-11.
32. Fleurette J. Diamidines aromatiques. In: Fleurette J, Freney J, Reverdy ME, eds. Antiseptie et Désinfection. Paris, France: ESKA Editions, 1995; 320-4.
33. Fotakis G, Timbrell JA. In vitro cytotoxicity assays: Comparison of LDH, neutral red, MTT and protein assay in hepatoma cell lines following exposure to cadmium chloride. Toxicol Lett 2006; 160 171-7.
34. Weyerman J, Lochmann D, Zimmer A. A practical note on the use of cytotoxicity assays. Int J Pharm 2005; 288: 369-76.
35. Giacometti A, Cirioni O, Barchiesi F et al. Antimicrobial activity of polycationic peptides. Peptides 1999; 20: 1265-73.
36. Powers JP, Hancock RE. The relationship between peptide structure and antibacterial activity. Peptides 2003; 24: 1681-91.